Latest Conference Articles

Frontline ibrutinib and rituximab plus fludarabine, cyclophosphamide, and rituximab improved quality of life in patients with chronic lymphocytic leukemia; ibrutinib given continuously maintained the improved quality of life, and it did not decline over time.

Tisagenlecleucel showed similar efficacy outcomes and a more favorable safety profile in real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia versus the ELIANA trial.

The XVd regimen demonstrated comparable efficacy and safety in patients with multiple myeloma who had high-risk or standard-risk cytogenetic features.

In patients with cancer, anxiety and depression can influence how they view cancer clinical trials, which leads to low enrollment.

Patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome had higher mortality rates after being diagnosed with COVID-19 than those with COVID-19 who did not have cancer.

In patients with largely resistant CP-CML, ponatinib showed clinical activity when administered at the 45 mg compared with lower doses.

The use of isatuximab with the RVd regimen in the induction phase may improve minimal residual disease negativity rates in patients with multiple myeloma, phase 3 results show.

High antibody levels were observed in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA-1273 SARS CoV-2 vaccination.

No overlapping toxicities and a tolerable safety profile were seen with the addition of talquetamab to daratumumab in a population of patients with relapsed/refractory multiple myeloma.

In patients with relapsed or refractory marginal zone lymphoma, parsaclisib produced a clinical response.

Higher sustained MRD-negativity rates were observed among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone

Looking at frontline venetoclax based combinations shows promise for fit patients with CLL.

In an analysis of the phase 3 GLOW study, data showed promise for the use of ibrutinib/venetoclax in the frontline setting.

New results from the CAPTIVATE study demonstrated that treatment with ibrutinib and venetoclax in the first-line setting of patients with CLL continues to elicit durable responses to placebo.

Data from the phase 2 VISION trial showed that restarting treatment with the combination was feasible in a select group of patients who initially had undetectable MRD after 15 cycles of treatment.

The use of ibrutinib plus loncastuximab tesirine induced encouraging anti-tumor activity and a manageable safety profile in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma, according to results from an interim analysis of the LOTIS-3 trial.

Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone improved hematologic and organ responses after 18 months of follow-up in the phase 3 ANDROMEDA study.

Liso-cel demonstrated meaningful EFS improvement as a second-line therapy in patients with LBCL.

In frail and elderly patients with multiple myeloma who are treated in the relapsed setting, a phase 2 trial shows promise of the daratumumab/ixazomib combination when given without dexamethasone.

Compared to those who waited and received second line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma, patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival.

A combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate (ORR) of 71%, in NDMM.

Mark Roschewski, MD, discusses the role Bruton’s tyrosine kinase inhibitor acalabrutinib has in aggressive B-cell lymphoma subgroups.

Alexandra S. Zimmer, MD, discusses the safety of the combination of the T-DM1 ado-trastuzumab emtansine and temozolomide, for the prevention of further brain metastases in patients with HER2-positive breast cancer with brain metastases.

In the phase 2 I-SPY 2 platform trial, receipt of targeted neoadjuvant chemotherapy did not appear to be based on race.

Adverse events in patients with high-risk HER2-negative early breast cancer treated with chemotherapy before olaparib may be resolved after therapy is complete.

Alexandra Higgins, MD, discusses when to use ado-trastuzumab emtansine in patients with HER2-positive breast cancer, and how to address particular adverse events that patients may develop while on treatment.

Samuraciclib plus fulvestrant demonstrates activity in patients with HR-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

Circulating tumor DNA should be used early and often by physcians who treat patients with early-stage triple-negative breast cancer.

Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.

Updated data from the PHOEBE trial show that pyrotinib plus capecitabine improved overall survival in patients with HER2-positive breast cancer compared with lapatinib plus capecitabine.